This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.
Read original at benzingaStocks · News reference
Nuvation Bio Announces Positive Updated Phase 2 Data And Expansion From Safusidenib Clinical Trial In Newly-Diagnosed Grade 2 Glioma Patients Outside The U.S.
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-upNew Phase 3 study to evaluate safusidenib in newly
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 12:09 PM
- Checked
- Jul 20, 2026, 12:09 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated coverage on Builders FirstSource, Inc and Nuvation Bio Inc.
Read original at benzingaThis Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
Read original at benzingaCantor Fitzgerald Initiates Coverage On Nuvation Bio with Overweight Rating
Cantor Fitzgerald analyst Li Watsek initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweight rating.
Read original at benzinga